GLP Watchdog

altRX vs GoodRx

altRX has an open FDA warning letter dated June 8, 2026. GoodRx has none. On brand-name tirzepatide pen, GoodRx costs $11,400 less a year at standing rates: $299 a month against $1,249 a month at altRX.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

altRX / GoodRx

Featured pick (affiliate partner)

altRX logo

altRX

8.8/10

GoodRx logo

GoodRx

7.8/10

FDA warning letters
None on record
Pharmacy
  • RedRock Pharmacy503A
  • Health Warehousetype not stated
  • Precision Medicinetype not stated
  • and 1 more
Brand-name only; no compounding
Lowest standing price
$89/moCompounded semaglutide injection
$149/moFoundayo (orforglipron) pill
States
All 50 states
48 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit altRX
Visit GoodRx

altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. GoodRx pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, GoodRx 7.8). How we are paid

What the record shows

  1. 01

    altRX has an open FDA warning letter dated June 8, 2026. GoodRx has none.

  2. 02

    altRX names four pharmacies. GoodRx sells brand-name medication only.

  3. 03

    On brand-name tirzepatide pen, GoodRx costs $11,400 less a year at standing rates: $299 a month against $1,249 a month at altRX.

  4. 04

    Only altRX lists a price for compounded semaglutide injection, compounded tirzepatide injection and brand-name semaglutide pen. Only GoodRx lists a price for Foundayo (orforglipron) pill.

  5. 05

    AltRX covers two states GoodRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

altRX

GoodRx

Brand-name tirzepatide pen

$1,249/mo

$14,988 a year

$299/moLower

$3,588 a year

Compounded semaglutide injection

$89/mo

$1,068 a year

Not sold or not priced
Compounded tirzepatide injection

$149/mo

$1,788 a year

Not sold or not priced
Brand-name semaglutide pen

$1,149/mo

$13,788 a year

Not sold or not priced
Foundayo (orforglipron) pill
Not sold or not priced

$149/mo

$1,788 a year

Price includes
Medication, clinician visits, shipping
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; multi-month plans are prepaid and non-refundable
None
Refunds
All payments are final and non-refundable, except a partial refund if you are medically disqualified
Services and medication are generally non-refundable

Read off each seller’s own pages. altRX: September 28, 2026. GoodRx: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for altRX

8.8/10
Featured pick (affiliate partner)
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which GoodRx does not price
  • Open FDA warning letter, June 8, 2026
Visit altRX

The case for GoodRx

7.8/10
  • No FDA warning letter on record
  • $11,400 a year less on brand-name tirzepatide pen
  • Sells Foundayo (orforglipron) pill, which altRX does not price
Visit GoodRx

Scores

altRX 8.8 · GoodRx 7.8 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
8.7

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
5.0

Trust & Safety15%

6.0A
vs
B
6.0

Accessibility10%

10.0A
vs
B
9.7

Support10%

7.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

altRX vs GoodRx: questions

altRX has an open FDA warning letter dated June 8, 2026. GoodRx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
altRX names four pharmacies. GoodRx sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
GoodRx, by $11,400 a year at standing rates. altRX: $1,249 a month, about $14,988 a year. GoodRx: $299 a month, about $3,588 a year.
altRX states you can cancel at any time; refunds: all payments are final and non-refundable, except a partial refund if you are medically disqualified. GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable.
altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. GoodRx pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, GoodRx 7.8).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks